Details
Stereochemistry | RACEMIC |
Molecular Formula | C18H28N2O.ClH.H2O |
Molecular Weight | 342.904 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.CCCCN1CCCCC1C(=O)NC2=C(C)C=CC=C2C
InChI
InChIKey=HUCIWBPMHXGLFM-UHFFFAOYSA-N
InChI=1S/C18H28N2O.ClH.H2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H;1H2
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11895133
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11895133
Bupivacaine is a widely used local anesthetic agent. Bupivacaine is often administered by spinal injection prior to total hip arthroplasty. It is also commonly injected into surgical wound sites to reduce pain for up to 20 hours after surgery. In comparison to other local anesthetics it has a long duration of action. It is also the most toxic to the heart when administered in large doses. Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Bupivacaine binds to the intracellular portion of sodium channels and blocks sodium influx into nerve cells, which prevents depolarization. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. The analgesic effects of bupivicaine are thought to potentially be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia. Bupivacaine sometimes used in combination with epinephrine to prevent systemic absorption and extend the duration of action.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2072 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12761351 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EXPAREL Approved UseBupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (See WARNINGS .) Experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of Bupivacaine Hydrochloride in these patients. Bupivacaine Hydrochloride is not recommended for intravenous regional anesthesia (Bier Block). (See WARNINGS .) The routes of administration and indicated Bupivacaine Hydrochloride concentrations are: • local infiltration 0.25% • peripheral nerve block 0.25% and 0.5% • retrobulbar block 0.75% • sympathetic block 0.25% • lumbar epidural 0.25%, 0.5%, and 0.75% (0.75% not for obstetrical anesthesia) • caudal 0.25% and 0.5% • epidural test dose 0.5% with epinephrine 1:200,000 • dental blocks 0.5% with epinephrine 1:200,000 (See DOSAGE AND ADMINISTRATION for additional information.) Standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of Bupivacaine Hydrochloride. Launch Date2011 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
952 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
810 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3868 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4096 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25776489/ |
75 mg single, epidural dose: 75 mg route of administration: Epidural experiment type: SINGLE co-administered: |
BUPIVACAINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3344993/ |
2.5 mg/kg single, caudal dose: 2.5 mg/kg route of administration: Caudal experiment type: SINGLE co-administered: |
BUPIVACAINE blood | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3344993/ |
2.5 mg/kg single, caudal dose: 2.5 mg/kg route of administration: Caudal experiment type: SINGLE co-administered: |
BUPIVACAINE blood | Homo sapiens population: UNHEALTHY age: NEWBORN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 1 times / day single, intramuscular Studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, 11 months n = 1 Health Status: healthy Age Group: 11 months Population Size: 1 Sources: |
Other AEs: Ventricular tachycardia... |
103 mg 1 times / day single, intravenous MTD Dose: 103 mg, 1 times / day Route: intravenous Route: single Dose: 103 mg, 1 times / day Sources: |
healthy, mean age 28 years n = 12 Health Status: healthy Age Group: mean age 28 years Sex: M Population Size: 12 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ventricular tachycardia | 40 mg 1 times / day single, intramuscular Studied dose Dose: 40 mg, 1 times / day Route: intramuscular Route: single Dose: 40 mg, 1 times / day Sources: |
healthy, 11 months n = 1 Health Status: healthy Age Group: 11 months Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Horner's syndrome due to epidural analgesia. | 1998 Dec |
|
Spinal cord compression from precipitation of drug solute around an epidural catheter. | 1998 Oct |
|
Postoperative extradural infusions in children: preliminary data from a comparison of bupivacaine/diamorphine with plain ropivacaine. | 1999 |
|
[Bupivacaine-induced meningitis]. | 1999 Aug |
|
The influence of baricity on the haemodynamic effects of intrathecal bupivacaine 0.5%. | 1999 May |
|
A multicentre trial of ropivacaine 7.5 mg x ml(-1) vs bupivacaine 5 mg x ml(-1) for supra clavicular brachial plexus anesthesia. | 1999 Oct |
|
Continuous paravertebral extrapleural infusion for post-thoracotomy pain management. | 1999 Oct |
|
Ropivacaine in peribulbar block: a comparative study with bupivacaine. | 1999 Sep |
|
Bupivacaine-induced myocardial depression and pulmonary edema: a case report. | 2000 Jul |
|
The dose-response of intrathecal sufentanil added to bupivacaine for labor analgesia. | 2000 Jun |
|
Lumbar sympathetic block for sympathetically maintained pain: changes in cutaneous temperatures and pain perception. | 2000 Jun |
|
Mental status change and aphasia after labor analgesia with intrathecal sufentanil/bupivacaine. | 2000 May |
|
Optimal dose of intrathecal clonidine added to sufentanil plus bupivacaine for labour analgesia. | 2000 Sep |
|
Stress-induced osteolysis of distal clavicle: imaging patterns and treatment using CT-guided injection. | 2001 |
|
[Bupivacaine in continuous epidural infusion using a portable mechanical devise for postoperative analgesia after surgery for hernia of the lumbar disk]. | 2001 Feb |
|
[A case of cardiac arrest with coronary artery spasm during lumbar epidural anesthesia]. | 2001 Feb |
|
[Anesthetic management for the correction of pectus excavatum using pectus bar under video-assistance]. | 2001 Feb |
|
Subarachnoid sufentanil for early postoperative pain management in orthopedic patients: a placebo-controlled, double-blind study using spinal microcatheters. | 2001 Feb |
|
Is comparative cardiotoxicity of S(-) and R(+) bupivacaine related to enantiomer-selective inhibition of L-type Ca(2+) channels? | 2001 Feb |
|
Extended femoral nerve sheath block after total hip arthroplasty: continuous versus patient-controlled techniques. | 2001 Feb |
|
Levobupivacaine for epidural analgesia in labor: the sparing effect of epidural fentanyl. | 2001 Feb |
|
Transient neurologic symptoms after spinal anesthesia with lidocaine in obstetric patients. | 2001 Feb |
|
Does pregnancy protect against intrathecal lidocaine-induced transient neurologic symptoms? | 2001 Feb |
|
Epidural naloxone reduces intestinal hypomotility but not analgesia of epidural morphine. | 2001 Jan |
|
Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). | 2001 Jan |
|
Digitally assisted acromioplasty: the effect of interscalene block on this new surgical technique. | 2001 Jan |
|
Clonidine combined with a long acting local anesthetic does not prolong postoperative analgesia after brachial plexus block but does induce hemodynamic changes. | 2001 Jan |
|
Bupivacaine wound instillation via an electronic patient-controlled analgesia device and a double-catheter system does not decrease postoperative pain or opioid requirements after major abdominal surgery. | 2001 Jan |
|
Intrathecal low-dose bupivacaine versus lidocaine for in vitro fertilization procedures. | 2001 Jan-Feb |
|
Combined spinal and epidural anesthesia with low doses of intrathecal bupivacaine in women with severe preeclampsia: a preliminary report. | 2001 Jan-Feb |
|
Randomized clinical trial of local bupivacaine perfusion versus parenteral morphine infusion for pain relief after laparotomy. | 2001 Mar |
|
Corneal sensation after topical anesthesia. | 2001 Mar |
|
Discomfort with fine-needle aspiration cytology of the breast. | 2001 Mar 10 |
|
Postoperative narcotic requirement after microscopic lumbar discectomy is not affected by intraoperative ketorolac or bupivacaine. | 2001 Mar 15 |
|
Assessment of wound infiltration with bupivacaine in women undergoing day-case gynecological laparoscopy. | 2001 Mar-Apr |
Sample Use Guides
single-dose administration only. maximum dosage of EXPAREL ((Bupivacaine Liposome Injectable Suspension) should not exceed 266 mg (20 mL, 1.3% of undiluted drug).
Route of Administration:
Intravascular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27195613
Bupivacaine increased the phosphorylation of GSK-3β(Tyr216) in ovarian carcinoma (SKOV-3) but without measurable effect in prostate carcinoma (PC3). GSK-3β inhibition and siRNA gene knockdown decreased bupivacaine induced cell death in SKOV-3 but not in PC3.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
||
|
FDA ORPHAN DRUG |
510515
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT001512
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
DTXSID501323779
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
5282419
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
100000088212
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
7TQO7W3VT8
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
C28876
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1098
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
BUPIVACAINE HYDROCHLORIDE
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | Description: A white, crystalline powder; odourless. Solubility: Soluble in 25 parts of water and in 8 parts of ethanol (~750 g/l) TS; slightly soluble in ether R. Category: Local anaesthetic. Storage: Bupivacaine hydrochloride should be kept in a well-closed container. Definition: Bupivacaine hydrochloride contains not less than 98.5% and not more than 101.0% of C18H28N2O,HCl, calculated with reference to the dried substance. | ||
|
1078507
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
31322
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
267396
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB21381
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
SUB00902MIG
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
60789
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
m2769
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
7TQO7W3VT8
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY | |||
|
73360-54-0
Created by
admin on Fri Dec 15 18:29:17 GMT 2023 , Edited by admin on Fri Dec 15 18:29:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD